Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -10 of 36
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
Arimidex Observational: Reason for and Effect of Change From Tamoxifen
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase IV
Treatment
Completed
18 and over
Pharmaceutical / Industry
D5392NL0002
ARREST, NCT00246961
Last Modified:
1/15/2008
 
First Published:
8/1/2001
2.
Phase II/III Randomized Study of Anastrozole With or Without Trastuzumab (Herceptin) in Postmenopausal Women With Hormone-Receptor Positive HER2-Overexpressing Metastatic Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Treatment
Closed
18 and over
Pharmaceutical / Industry
ROCHE-BO16216
CWRU-030118, GENENTECH-H2223g, ROCHE-1100, ROCHE-B016216F, NCT00022672
Last Modified:
6/1/1998
3.
Phase III Randomized, Double-Blind Study of Anastrozole vs Tamoxifen as First-Line Therapy in Postmenopausal Women with Advanced Breast Cancer (Summary Last Modified 06/98)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
any age
Pharmaceutical / Industry
ZENECA-1033IL/0030
NCI-V96-1049
Last Modified:
7/18/2005
 
First Published:
7/1/1998
4.
Phase III Randomized Study of ICI 182780 (Faslodex) versus Anastrozole in Postmenopausal Women with Advanced Breast Cancer (Summary Last Modified 11/1999)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
Not specified
NCI, Pharmaceutical / Industry
RPCI-DS-97-29
ZENECA-9238IL/0021, NCI-G98-1412
Last Modified:
8/28/2008
 
First Published:
1/26/2003
5.
Phase III Randomized Study of Anastrozole Versus Tamoxifen in Postmenopausal Women With Ductal Carcinoma in Situ of the Breast Undergoing Lumpectomy and Radiotherapy (Arm I and Arm II Closed to Accrual as of 6/15/06)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
Postmenopausal
NCI
NSABP-B-35
SWOG-NSABP-B-35, NCCTG-NSABP-B-35, ACOSOG-NSABP-B-35, NCT00053898
Last Modified:
1/27/2005
 
First Published:
1/26/2003
6.
Phase III Randomized Study of Adjuvant Cyclophosphamide, Epirubicin, Fluorouracil, and Docetaxel Versus Observation in Women With Relapsed Nonmetastatic Breast Cancer After Initial Conservative Surgery
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
18 to 65
Other
FRE-FNCLCC-PACS-03/003
EU-20237, NCT00053911
Last Modified:
11/3/2008
 
First Published:
7/26/2003
7.
Phase III Randomized Adjuvant Study of Exemestane Versus Anastrozole in Postmenopausal Women With Receptor-Positive Primary Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
Postmenopausal
NCI, Other
CAN-NCIC-MA27 (COMPANION)
NCCTG-MA27, CALGB-CAN-NCIC-MA27, ECOG-CAN-NCIC-MA27, SWOG-CAN-NCIC-MA27, NCIC-MA.27, NCT00066573, IBCSG-30-04, EUDRACT-2005-001893-28, MA27
8.
Anastrozole Biphosphonate Study in Postmenopausal Women With Hormone-Receptor-Positive Early Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Supportive care, Treatment
Completed
Postmenopausal
Pharmaceutical / Industry
D5392C00050
SABRE, NCT00082277
9.
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Completed
No age specified
Pharmaceutical / Industry
CFEM345D2411
NCT00248170
10.
Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Treatment
Closed
No age specified
Pharmaceutical / Industry
D6997L00002
9238SW/0001, FACT, NCT00256698
Select All on One Page
1
2
3
4
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute